Introduction

Virbac AH Logo Blue

Company name: Virbac Limited

Address: Woolpit Business Park

Windmill Avenue

Woolpit

Bury St Edmunds

Suffolk

IP30 9UP

Telephone: 01359 243243

Fax: 01359 243200

Website: www.virbac.co.uk

Presentation

Live freeze-dried pellet for suspension for injection.

Each single dose vial contains Canine distemper virus, strain Onderstepoort³ 104.0 TCID50,

Canine adenovirus 2, strain Manhattan LPV3³ 104.0 TCID50, Canine parvovirus, strain 154³ 107.0 TCID50.

Uses

The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, infectious canine hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2.

For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and reduce viral excretion caused by canine parvovirus infection; to reduce clinical signs of infectious canine hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.

Specific claims

Onset of immunity: for the CAV2 component two weeks and for the CDV and CPV components one week after vaccination.

Duration of immunity: three years.

Dosage and administration

The contents of one vial of reconstituted vaccine should be injected subcutaneously.

Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of Canigen Solvent, Canigen Lepto 2 or Canigen Rabies.

Sterile equipment should be used for administration.

Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.

Vaccination regime

Primary course vaccination

A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose should be given 2-4 weeks later i.e. at 10 weeks of age or older.

Booster vaccination

To maintain protection a single booster dose is recommended every three years.

The product can be used in pregnant bitches which have previously been vaccinated with Canigen DHPPi, Canigen DHP, Canigen PPi or Canigen Pi

Contra-indications, warnings, etc

After subcutaneous administration with Canigen Solvent or Canigen Lepto 2 a diffuse swelling, up to 5 mm in diameter, may be observed at the site of injection in approximately 10% of animals. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.

After subcutaneous administration with Canigen Rabies, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing.

In very rare cases a transient rise in body temperature and/or a transient acute hypersensitivity reaction (anaphylaxis) - with signs that may include lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse - may occur shortly after vaccination.

Only healthy dogs should be vaccinated. Dogs should not be exposed to unnecessary risk of infection within the first 2 weeks after completion of the vaccination regimen.

While the canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation, there is no evidence that this results in clinical symptoms if non-vaccinated animals are infected.

No information is available on the safety and efficacy of this vaccine when used with any other vaccine except Canigen Lepto 2 or Canigen Rabies. It is therefore recommended that no other vaccines than these should be administered within 14 days before or after vaccination with Canigen DHP.

Do not mix with any other vaccine/immunological product except with Canigen Solvent, Canigen Lepto 2 or Canigen Rabies.

The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2 and CPV that are likely to be encountered under field conditions.

Operator warnings

In the case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.

Withdrawal period

Not applicable.

For animal treatment only. Keep out of reach and sight of children.

Pharmaceutical precautions

The product should be stored between +2°C and +8°C. Do not freeze. Protect from light.

Reconstituted vaccine

Store in a refrigerator at +2°C to +8°C with care being taken to avoid prolonged or repetitive exposure to high ambient temperature following withdrawal from the refrigerator prior to use.

Shelf life after reconstitution: 30 minutes.

Disposal advice

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant, in accordance with the national requirements.